The US Food and Drug Administration approved Novartis AG's NOVN.S therapy for the treatment of patients with a type of advanced prostate cancer that has spread to other parts of the body, the drugmaker said on Wednesday.
Novartis' Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments.
console.log("BODY2. CatId is:"+catID);if(catID==120){console.log("BODY. YES for anyclip script");document.getElementsByClassName("divConnatix")[0].style.display ="none";var script = document.createElement('script'); script.src = 'https://player.anyclip.com/anyclip-widget/lre-widget/prod/v1/src/lre.js'; script.setAttribute('pubname','jpostcom'); script.setAttribute('widgetname','0011r00001lcD1i_12258'); document.getElementsByClassName('divAnyClip')[0].appendChild(script);}else if(catID!=69 && catID!=2){console.log("BODY. YES for vidazoo script");document.getElementsByClassName("divConnatix")[0].style.display ="none"; var script = document.createElement('script'); script.src = 'https://static.vidazoo.com/basev/vwpt.js'; script.setAttribute('data-widget-id','60fd6becf6393400049e6535'); document.getElementsByClassName('divVidazoo')[0].appendChild(script); }The company bought the therapy as part of its $2.1 billion purchase of cancer drugmaker Endocyte in 2018.
Pluvicto is a precision treatment combining a targeting compound, or ligand, with a cancer-killing radioactive particle, Novartis said.
The company said it has submitted marketing authorization for Pluvicto to the European Medicines Agency and other health authorities.
Two late-stage studies evaluating Pluvicto in earlier lines of treatment for metastatic prostate cancer are underway, according to Novartis.
